Bluejay Diagnostics, INC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 142,728 shares, representing 9.99% of Bluejay Diagnostics, Inc.'s common stock.

Ayrton Capital LLC, along with affiliated entities, has disclosed a beneficial ownership of 9.99% in Bluejay Diagnostics, Inc., primarily through shares and exercisable warrants.

Intracoastal Capital LLC and its principals have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Bluejay Diagnostics, Inc.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 51,061 shares, representing 4.99% of the outstanding common stock of Bluejay Diagnostics, Inc.

Intracoastal Capital LLC and its principals have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership in Bluejay Diagnostics, Inc.

Northstrive Fund II LP and its manager, Braeden Lichti, have disclosed significant beneficial ownership in Bluejay Diagnostics, Inc., with Lichti now holding over 5% of common stock.

Braeden Lichti and Northstrive Fund II LP have disclosed a combined 5.01% beneficial ownership stake in Bluejay Diagnostics, Inc. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a 9.99% passive ownership stake in Bluejay Diagnostics, Inc. common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, reporting a reduced beneficial ownership of 221,251 shares, or 0.82%, in Bluejay Diagnostics, Inc. as of December 31, 2024.

Anson Funds Management LP and affiliated entities have filed an Amendment No. 1 to Schedule 13G, disclosing a 1.4% beneficial ownership stake in Bluejay Diagnostics, Inc. as of December 31, 2024.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz have reported a passive 4.9% beneficial ownership stake in Bluejay Diagnostics, Inc. as of December 31, 2024.